These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics. Tibes R; Trent J; Kurzrock R Annu Rev Pharmacol Toxicol; 2005; 45():357-84. PubMed ID: 15822181 [TBL] [Abstract][Full Text] [Related]
44. Combining inhibitors of ALK and ROS1 with other agents for the treatment of non-small cell lung cancer. Shaw AT Clin Adv Hematol Oncol; 2015 May; 13(5):282-4. PubMed ID: 26352769 [No Abstract] [Full Text] [Related]
45. Emerging Biomarkers in Personalized Therapy of Lung Cancer. Cagle PT; Raparia K; Portier BP Adv Exp Med Biol; 2016; 890():25-36. PubMed ID: 26703797 [TBL] [Abstract][Full Text] [Related]
46. [ALK inhibitor]. Mano H Gan To Kagaku Ryoho; 2011 Jan; 38(1):27-30. PubMed ID: 21368458 [TBL] [Abstract][Full Text] [Related]
47. Presurgical targeted therapy with tyrosine kinase inhibitors for advanced renal cell carcinoma: clinical results and histopathological therapeutic effects. Kondo T; Hashimoto Y; Kobayashi H; Iizuka J; Nishikawa T; Nakano M; Tanabe K Jpn J Clin Oncol; 2010 Dec; 40(12):1173-9. PubMed ID: 20696817 [TBL] [Abstract][Full Text] [Related]
48. The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC). Golding B; Luu A; Jones R; Viloria-Petit AM Mol Cancer; 2018 Feb; 17(1):52. PubMed ID: 29455675 [TBL] [Abstract][Full Text] [Related]
49. The Use of EGFR Tyrosine Kinase Inhibitors in EGFR Wild-Type Non-Small-Cell Lung Cancer. Stinchcombe TE Curr Treat Options Oncol; 2016 Apr; 17(4):18. PubMed ID: 26961971 [TBL] [Abstract][Full Text] [Related]
52. The Revised College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Guideline: A Step Forward for Molecular Cytopathology. Aisner DL Arch Pathol Lab Med; 2018 Jun; 142(6):684-685. PubMed ID: 29595315 [No Abstract] [Full Text] [Related]
53. [Kinase inhibitors in oncology : What is new?]. Riedmann K; Bassermann F; Jost PJ Internist (Berl); 2019 May; 60(5):540-544. PubMed ID: 30859279 [TBL] [Abstract][Full Text] [Related]
54. Targeted anti-cancer therapy in the elderly. Gonsalves W; Ganti AK Crit Rev Oncol Hematol; 2011 Jun; 78(3):227-42. PubMed ID: 20599391 [TBL] [Abstract][Full Text] [Related]
55. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC. Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323 [TBL] [Abstract][Full Text] [Related]
56. Best Use of the Tyrosine Kinase Inhibitors in Progressive Differentiated Thyroid Cancer: Discussion. Tuttle RM; Brose MS Clin Adv Hematol Oncol; 2016 May; 14(5 Suppl 9):12-3. PubMed ID: 27168343 [No Abstract] [Full Text] [Related]
57. [Is chemotherapy still a valid option for oncogene-addicted lung cancer? Yes]. Besse B Bull Cancer; 2015 Jun; 102(6 Suppl 1):S93-5. PubMed ID: 26118884 [TBL] [Abstract][Full Text] [Related]
58. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer. Zhang K; Yuan Q J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005 [TBL] [Abstract][Full Text] [Related]
59. Current and future targeted therapies for non-small-cell lung cancers with aberrant EGF receptors. Kanthala S; Pallerla S; Jois S Future Oncol; 2015; 11(5):865-78. PubMed ID: 25757687 [TBL] [Abstract][Full Text] [Related]